VePesid

(etoposide)

ApprovedSmall molecule

Etoposide is a chemotherapy drug used to treat certain types of cancer, including lung cancer, testicular cancer, and lymphomas, by stopping cancer cells from dividing and growing.[2] VePesid is currently approved and in use across 147 indications[4].[1]

VePesid is one of 1623 small molecule programs targeting Glioma. It is currently in Approved.

147

Indications

1,137

Total Trials

Active Trials

1,622

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Small Cell CarcinomaActive, not recruiting

EpendymomaActive, not recruiting

FibrosarcomaActive, not recruiting

SeminomaActive, not recruiting

HIV InfectionActive, not recruiting

Non-Hodgkins LymphomaApproved

NeutropeniaActive, not recruiting

Merkel Cell Skin CancerApproved

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

GliomaPhase 3

Active, not recruiting

Small Cell CarcinomaPhase 2

Active, not recruiting

EpendymomaPhase 2

Active, not recruiting

FibrosarcomaPhase 2

Active, not recruiting

SeminomaPhase 2

Active, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

NeutropeniaPhase 2

Active, not recruiting

Merkel Cell Skin CancerApproved

Approved

Adult Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Showing 10 of 147 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

VePesid

AAvyxa

Approved

14 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

MS Contin

Merck & Co.

Preclinical

2 5

Zolymbus

AbbVie

Preclinical

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Lymphoma

NCT02337985

Phase 3Active, not recruiting

Neuroblastoma

NCT02176967

Q4 2026

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT02883049

Phase 2Recruiting

Neuroblastoma

NCT02605421

Phase 3Recruiting

Thymic Carcinoma

NCT02633514

Phase 3Recruiting

Lymphoma

NCT04638790

Clinical

Trials by Indication[1]

Lymphoma33 trials

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Unknown status·SSamsung Medical Center·Phase 2·NCT02544425·27 enrolled

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Recruiting·SState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia·Phase 3·NCT04638790·300 enrolled

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown status·—·Phase 1/2·NCT05776407·12 enrolled

Show 30 more trials

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

Completed·RRuijin Hospital·Phase 2·NCT02825147·40 enrolled

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting·—·Phase 2·NCT03749018·30 enrolled

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Unknown status·SSun Yat-sen University·Phase 2·NCT03321890·102 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002941·69 enrolled

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 3·NCT02631239·256 enrolled

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00822120·371 enrolled

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Completed·PPolish Lymphoma Research Group·Phase 2·NCT01481272·77 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00255723·98 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT01775475·7 enrolled

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

Completed·SStanford University·Phase 2·NCT00002715·50 enrolled

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

Completed·—·Phase 1/2·NCT00562978·54 enrolled

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01920932·77 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00080886·68 enrolled

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Completed·MMontefiore Medical Center·Phase 2·NCT00002461·35 enrolled

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01193842·107 enrolled

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00028665·37 enrolled

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003631·118 enrolled

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT03586999·18 enrolled

Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Unknown status·LLymphoma Trials Office·Phase 1/2·NCT00032149·30 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Completed·SSwiss Cancer Institute·Phase 3·NCT00003215·400 enrolled

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005985·213 enrolled

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05008224·146 enrolled

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Active, not recruiting·—·Phase 1·NCT02337985·10 enrolled

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT01569204·100 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Completed·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT02686346·53 enrolled

Small Cell Lung Cancer21 trials

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Completed· Roche logo

Roche·Phase 3·NCT02763579·503 enrolled

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Withdrawn·UUniversity of Washington·Phase 2·NCT05161533

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03043872·987 enrolled

Show 18 more trials

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00042978·55 enrolled

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04951115·6 enrolled

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00388960·99 enrolled

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00041054·41 enrolled

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191139·64 enrolled

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Terminated·UUniversity of California, Davis·Phase 1·NCT00807755·5 enrolled

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT00004176·34 enrolled

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·—·Phase 3·NCT00041015·4 enrolled

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00453154·156 enrolled

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03711305·462 enrolled

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04702880·120 enrolled

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Unknown status·TTaizhou HoudeAoke Biomedical Co., Ltd.·Phase 2·NCT04740021·46 enrolled

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT02289690·221 enrolled

Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00066742·72 enrolled

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT04622228·56 enrolled

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

Terminated·GGiuseppe Giaccone·Phase 1/2·NCT02748889·1 enrolled

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

Unknown status·AAlaunos Therapeutics·Phase 3·NCT01555710·548 enrolled

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Withdrawn·MMassachusetts General Hospital·Phase 2·NCT00916669

Acute Lymphoblastic Leukemia17 trials

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Terminated· Sanofi logo

Sanofi·Phase 2·NCT03860844·67 enrolled

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003728·1,500 enrolled

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

Show 14 more trials

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01614197·16 enrolled

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00107354

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002704·156 enrolled

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Completed·CChildren's Oncology Group·Phase 1/2·NCT00098839·134 enrolled

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00557193·218 enrolled

Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia

Completed·NNorthwestern University·Phase 1/2·NCT00004898·6 enrolled

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05192889·35 enrolled

Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia

Completed·WWashington University School of Medicine·Phase 1·NCT01331590·13 enrolled

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Completed·—·Phase 1/2·NCT00576979·51 enrolled

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02883049·5,949 enrolled

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00002961·43 enrolled

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03007147·475 enrolled

Neuroblastoma11 trials

A Study of N9 Chemotherapy in Children With Neuroblastoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04947501·26 enrolled

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00287950·120 enrolled

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled

Show 8 more trials

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT02176967·621 enrolled

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma

Completed·EEuropean Infant Neuroblastoma Study Group - 1999·Phase 2·NCT00025623

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Unknown status·UUniversity of Leicester·Phase 3·NCT00030719·175 enrolled

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Terminated·MM.D. Anderson Cancer Center·Phase 2/3·NCT00539500·3 enrolled

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Completed·—·Phase 2·NCT00253435·50 enrolled

Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00024193

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT01798004·150 enrolled

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00040872

Non-Small Cell Lung Cancer9 trials

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04989283

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Unknown status·TThird Military Medical University·Phase 2·NCT02733107·25 enrolled

Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00002550·429 enrolled

Show 6 more trials

A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00924209·7 enrolled

Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

Completed·—·Phase 3·NCT00216125·243 enrolled

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00042835·48 enrolled

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Withdrawn· Incyte logo

Incyte·Phase 3·NCT04203511

A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

Completed· Roche logo

Roche·Phase 1·NCT00776698·1 enrolled

Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer

Terminated·MMassachusetts General Hospital·Phase 1·NCT01565772·4 enrolled

69 more indications

Acute Myeloid Leukemia7 trials

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Completed·SSt. Jude Children's Research Hospital·Phase 3·NCT00703820·324 enrolled

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Completed·UUniversity of Ulm·Phase 3·NCT01237808·144 enrolled

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·AAlice Mims·Phase 1·NCT02299518·23 enrolled

Show 4 more trials

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Suspended·SSt. Jude Children's Research Hospital·Phase 2·NCT05955261·70 enrolled

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT01342887·6 enrolled

Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00052299·472 enrolled

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT03793478·65 enrolled

Germ Cell Tumor6 trials

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

Completed·CChildren's Oncology Group·N/A·NCT00066482·19 enrolled

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

Unknown status·SSamsung Medical Center·Phase 2·NCT02784054·25 enrolled

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Recruiting·BBeihua Kong·Phase 3·NCT02429687·129 enrolled

Show 3 more trials

Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02161692

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Terminated·UUNICANCER·Phase 2·NCT00003852·45 enrolled

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Recruiting·CChildren's Oncology Group·Phase 3·NCT03067181·1,780 enrolled

Chemotherapy4 trials

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Recruiting·EEmory University·Phase 2·NCT04469530·55 enrolled

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting·NNew York Medical College·Phase 2·NCT02393157·25 enrolled

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Completed·CChildren's Oncology Group·Phase 3·NCT00304070·78 enrolled

Show 1 more trial

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT04116359

Breast Cancer3 trials

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002836·184 enrolled

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01492556·100 enrolled

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Recruiting·—·Phase 2·NCT06418594·30 enrolled

Lung Cancer3 trials

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 1/2·NCT01987232·32 enrolled

Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT04730999·54 enrolled

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449209·110 enrolled

Hodgkin's Disease3 trials

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00005578·219 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease

Completed·SStanford University·Phase 2·NCT00002714

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 2·NCT00004010·99 enrolled

Multiple Myeloma3 trials

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Completed·UUniversity of Washington·Phase 2·NCT01110135·43 enrolled

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Unknown status·SSwedish Medical Center·Phase 2·NCT03570983·100 enrolled

Stem Cell Transplant3 trials

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT02483000·3 enrolled

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·—·Phase 2·NCT00054327·34 enrolled

Acute Leukemia3 trials

Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01677949

Use of Topotecan in Patients With Refractory Acute Leukemia

Completed·UUS Department of Veterans Affairs·Phase 2·NCT00100477·10 enrolled

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00002912·3 enrolled

Bone Marrow Transplantation2 trials

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002552·40 enrolled

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00003436·2,000 enrolled

Osteosarcoma2 trials

Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504140·30 enrolled

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00667342·43 enrolled

Chronic Myelogenous Leukemia2 trials

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002800·60 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Ewing sarcoma2 trials

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

Completed·CChildren's Oncology Group·N/A·NCT00618813·35 enrolled

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Withdrawn·—·N/A·NCT01795430

Immunotherapy2 trials

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

Terminated·—·Phase 2·NCT04923776·2 enrolled

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Terminated·UUniversity of Washington·Phase 2·NCT04372927·1 enrolled

Stem Cell Transplantation2 trials

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004904

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

Unknown status·—·Phase 1·NCT00004086

Leukemia2 trials

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 2·NCT00939653·6 enrolled

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01000285·18 enrolled

Metastatic Prostate Cancer2 trials

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00028769·41 enrolled

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·GGroupe D'Etude des Tumeurs Uro-Genitales·Phase 2·NCT00627354·90 enrolled

Maintenance Therapy2 trials

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Completed·UUniversity of Ulm·Phase 2·NCT01180322·277 enrolled

Hematologic Malignancies2 trials

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Completed·SSally Arai·Phase 1·NCT00477035·22 enrolled

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00697671·48 enrolled

Myelodysplastic Syndrome2 trials

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02029950·50 enrolled

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT02521493·280 enrolled

Treatment2 trials

Treatment of Tumors of the Choroid Plexus Epithelium

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00500890·2 enrolled

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Recruiting·JJoanna Yi·Phase 1·NCT07059975·36 enrolled

Anaplastic Large Cell Lymphoma2 trials

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00006455·885 enrolled

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00354107·5 enrolled

Induction Therapy2 trials

Optimum Induction Therapy of Low-risk APL

Recruiting·PPeking University People's Hospital·N/A·NCT05832320·74 enrolled

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting·—·Phase 2·NCT06221683·500 enrolled

Small Cell Lung Carcinoma1 trial

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01439568·90 enrolled

Methotrexate1 trial

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children with Recurrent Posterior Fossa Brain Tumors

Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT02905110·3 enrolled

Glioma1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

Completed·CChildren's Oncology Group·Phase 1·NCT00003935·31 enrolled

Kidney Cancer1 trial

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Completed·CChildren's Oncology Group·Phase 3·NCT00002611·3,031 enrolled

Combination Therapy1 trial

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT06030258·120 enrolled

Ewing's Sarcoma1 trial

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00061893·38 enrolled

Advanced Solid Tumors1 trial

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04047862·446 enrolled

Superior Sulcus Tumor1 trial

Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00984997·38 enrolled

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

T-cell acute lymphoblastic leukemia1 trial

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02518750·3 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01900509·16 enrolled

Central Nervous System Lymphoma1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003632·30 enrolled

Cancer of Unknown Primary1 trial

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Unknown status·AAcademisch Ziekenhuis Maastricht·Phase 3·NCT00003558·140 enrolled

Metastatic Tumors1 trial

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

Brain Cancer1 trial

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04521946

Mantle Cell Lymphoma1 trial

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006747·4 enrolled

Diffuse Large B-Cell Lymphoma1 trial

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05784987·60 enrolled

Chemoradiotherapy1 trial

S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors

Completed·SSWOG Cancer Research Network·Phase 2·NCT00062439·46 enrolled

Advanced Stage1 trial

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

Anaplastic Astrocytoma1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003621·29 enrolled

Relapsed/Refractory1 trial

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Unknown status·—·Phase 2·NCT04405375·29 enrolled

Hematopoietic Stem Cell Mobilization1 trial

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Unknown status·—·N/A·NCT05510089·62 enrolled

Thymic Carcinoma1 trial

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Recruiting·FFudan University·Phase 3·NCT02633514·1 enrolled

Advanced Sarcoma1 trial

Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00002974·34 enrolled

Carboplatin1 trial

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Withdrawn· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT06719973

Liver Cancer1 trial

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03533582·537 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Newly Diagnosed1 trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting·CChildren's Oncology Group·Phase 3·NCT04293562·1,186 enrolled

Lenalidomide1 trial

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02636322·60 enrolled

Relapse1 trial

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Terminated·—·Phase 3·NCT02366663·3 enrolled

Soft Tissue Sarcoma1 trial

Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003052·340 enrolled

T-cell non-Hodgkin lymphoma1 trial

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Completed·UUniversity of Washington·Phase 1/2·NCT00601718·29 enrolled

CNS Tumors1 trial

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06528691·52 enrolled

Hematological Malignancies1 trial

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Recruiting·—·N/A·NCT05536154·68 enrolled

Pediatric Patients1 trial

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Unknown status·SSeattle Children's Hospital·N/A·NCT02015728·20 enrolled

Induction Chemotherapy1 trial

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Completed·MMassachusetts General Hospital·Phase 1·NCT01830777·22 enrolled

Rhabdomyosarcoma1 trial

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025363·150 enrolled

Central Nervous System Cancer1 trial

Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00053118·1 enrolled

Malignant Brain Tumors1 trial

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Unknown status·—·Phase 3·NCT00392886·120 enrolled

Celecoxib1 trial

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Completed·—·Phase 2·NCT00357500·101 enrolled

Ependymoma1 trial

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

Completed·CChildren's Oncology Group·Phase 2·NCT00027846·378 enrolled

Patients With Advanced Solid Tumors1 trial

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

Relapsed or Refractory1 trial

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025103·75 enrolled

Radiation Therapy1 trial

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

Completed·—·Phase 2·NCT00084838·25 enrolled

DLBCL1 trial

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03018626·402 enrolled

Unspecified1 trial

High-dose ICE With Amifostine

Completed·—·Phase 2·NCT00003657·24 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 10, 1983

VEPESID

NDA NDA018768

Dec 30, 1986

VEPESID

NDA NDA019557

May 17, 1996

ETOPOPHOS PRESERVATIVE FREE

NDA NDA020457

Feb 27, 1998

ETOPOPHOS PRESERVATIVE FREE

NDA NDA020906

Feb 13, 2026

AVOPEF

NDA NDA220200

Sources

References

[1]
ClinicalTrials.gov — 1137 trial records for etoposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — VePesid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — etoposide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for etoposide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA220200). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Avyxa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAvyxa